Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 201,530 | 387,626 | 205,326 | 90,963 | 141,207 |
| Marketable Securities | 508,941 | 600,058 | 662,553 | 757,241 | 757,745 |
| Receivables | 3,927 | N/A | N/A | N/A | N/A |
| Inventories | 4,139 | N/A | N/A | N/A | N/A |
| TOTAL | $753,927 | $1,022,752 | $900,658 | $882,598 | $934,706 |
| Non-Current Assets | |||||
| PPE Net | 49,926 | 51,728 | 52,402 | 53,732 | 58,717 |
| Investments And Advances | 229,534 | 63,785 | 98,322 | 24,703 | 78,463 |
| Intangibles | 35,250 | 36,000 | 0 | 0 | 0 |
| Other Non-Current Assets | 89,318 | 91,758 | 93,472 | 94,588 | 94,355 |
| TOTAL | $404,028 | $243,271 | $244,196 | $173,023 | $231,535 |
| Total Assets | $1,157,955 | $1,266,023 | $1,144,854 | $1,055,621 | $1,166,241 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,807 | 40,380 | 505 | 6,745 | 10,844 |
| Accrued Expenses | 78,276 | 69,776 | 97,846 | 33,299 | 39,413 |
| Other current liabilities | N/A | N/A | N/A | 40,938 | 31,929 |
| TOTAL | $90,083 | $110,156 | $98,351 | $90,146 | $91,057 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 227,215 | 224,261 | 27,210 | 33,724 | 42,554 |
| TOTAL | $232,694 | $229,769 | $32,742 | $39,278 | $48,131 |
| Total Liabilities | $322,777 | $339,925 | $131,093 | $129,424 | $139,188 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 159,847 | 158,710 | 158,592 | 146,662 | 146,212 |
| Common Shares | 1,924 | 1,913 | 1,888 | 1,793 | 1,783 |
| Retained earnings | -2,307,524 | -2,179,971 | -2,051,524 | -1,922,975 | -1,796,073 |
| Other shareholders' equity | -1,969 | -682 | 682 | 1,101 | 939 |
| TOTAL | $835,178 | $926,098 | $1,013,761 | $926,197 | $1,027,053 |
| Total Liabilities And Equity | $1,157,955 | $1,266,023 | $1,144,854 | $1,055,621 | $1,166,241 |